Lumora Inks Supply Agreement with Promega | GenomeWeb

NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Lumora today announced a supply agreement with Promega for use of its luciferase in Lumora's Bioluminescent Assay in Real-Time, or BART, technology.

The deal is the first commercial molecular diagnostic application for Promega's Ultra-Glo luciferase, Lumora said. Its BART technology, a novel reporter system, is used with isothermal nucleic acid amplification technology and causes a sample to light up when a diagnostic test result is positive.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.